The global graft versus host disease market is expected to grow at a CAGR of 7% from 2016-2021 and CAGR of 3% from 2019-2029. The market is expected to grow at a CAGR of 6% from 2016 to 2027. The market is estimated at $0.36bn in 2016, $0.51bn in 2021, and $0.64bn in 2026.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 162-page report you will receive 62 tables and 76 figures – all unavailable elsewhere.
The 162-page report provides clear detailed insight into the Graft versus Host Disease market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope
• Revenue and growth forecasts to 2027 for the global GVHD market
• Revenue and growth forecasts to 2027 for the leading countries
• GVHD patient number forecast to 2027 per leading country, segmented into total allogenic cases, first allogenic cases, acute GVHD and chronic GVHD
• Revenue and growth forecasts to 2027 for the leading segments of the GVHD market by treatment type
• Revenue and growth forecasts to 2027 for the leading drugs in the GVHD market.
Individual revenue forecasts to 2027 by treatment type:
• Prophylaxis GVHD
• Chronic GVHD
• Acute GVHD
Individual revenue forecasts to 2027 by product:
• Corticosteroids
– Methylprednisolone
– Budenofalk (effeverscent)
• ATG therapies
– Available ATG therapy (Thymoglobulin)
– Atege-Fresenius
• IL2Rα (CD25) inhibitors
– Simulect (Basiliximab)
– Leukotac (inolimomab)
• TNFα inhibitors
– Remicade (Infliximab)
– Enbrel (Etanercept)
– Co-stimulatory blockers
– Orencia (abatacept)
– Nulojix (belatacept)
• Other biologics
– Lemtrada (Alemtuzumab)
– Rituxan/MabThera (rituximab)
– Begedina (bt/9 anti-CD26)
• Calcineurin inhibitors
– Cyclosporine
• mTOR inhibitors
– Rapamune (sirolimus)
– Certican (everolimus)
• SOT therapies
– CellCept/Myfortic (mycophenolate mofetil)
– Prograf (tacrolimus)
• Anti-neoplastic therapies
– Velcade (bortezomib)
– Gleevec (imatinib)
– Methrotrexate
– Nipent (pentostatin)
– Cyclophosphamide
• Stem Cell Treatments
– In situ preparations of mesenchymal cells
– Prochymal (remestemcel-L)
• Extracorporeal Photophoresis
– Uvadex (Therakos)
Individual revenue forecasts to 2027 by country, further segmented by treatment type and by product:
• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
GVHD patient number forecasts to 2027 per leading country, segmented into:
• total allogenic cases
• first allogenic cases
• acute GVHD
• chronic GVHD
Visiongain’s study is intended for anyone requiring commercial analyses for the GVHD market. You find data, trends and predictions.
Buy our report today Global Graft versus Host Disease (GVHD) Market 2019-2029: Acute, Chronic and Prophylaxis GVHD.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1 Report Overview
1.1 Global Graft versus Host Disease (GVHD) Market Overview
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methodology
1.6.1 Primary Research
1.6.2 Secondary Research
1.6.3 Market Evaluation & Forecasting Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2. Graft versus Host Disease Background
2.1 Graft versus Host Disease Definition
2.2 Graft versus Host Disease Classifications
2.2.1 Acute graft-versus-host disease (GVHD)
2.2.2 Chronic graft-versus-host disease (GVHD)
2.2.3 Symptoms of Graft versus Host Disease
2.3 Grades of GvHD
3 Global GVHD Market 2016
3.1 Global GVHD Market, 2016
4 Global GHVD Market Forecast, 2016-2027
4.1 Key Findings
4.2 Key Market Challenges and Opportunities
5 Global GVHD Market by Product 2019-2029
6 Regional GVHD Market 2016-2026
6.1 Regional Breakdown of the GVHD Market, 2016
6.2 United States GVHD Market Forecast 2019-2029
6.2.1 U.S. GVHD Market Forecast by Products 2019-2029
6.2.2 U.S. GVHD Patient Number Forecast 2016-2027
6.3 Japan GVHD Market Forecast 2019-2029
6.3.1 Japan GVHD Market Forecast by Products 2019-2029
6.3.2 Japan GVHD Patient Number Forecast 2016-2027
6.4 France GVHD Market Forecast 2019-2029
6.4.1 France GVHD Market Forecast by Products 2019-2029
6.4.2 France GVHD Patient Number Forecast 2016-2027
6.5 Germany GVHD Market Forecast 2019-2029
6.5.1 Germany GVHD Market Forecast by Products 2019-2029
6.5.2 Germany GVHD Patient Number Forecast 2016-2027
6.6 Italy GVHD Market Forecast 2019-2029
6.6.1 Italy GVHD Market Forecast by Products 2019-2029
6.6.2 Italy GVHD Patient Number Forecast 2016-2027
6.7 Spain GVHD Market Forecast 2019-2029
6.7.1 Spain GVHD Market Forecast by Products 2019-2029
6.7.2 Spain GVHD Patient Number Forecast 2016-2027
6.8 United Kingdom GVHD Market Forecast 2019-2029
6.8.1 United Kingdom GVHD Market Forecast by Products 2019-2029
6.8.2 United Kingdom GVHD Patient Number Forecast 2016-2027
6.9 Key Findings
6.10 Treatment Goals
7 Leading Drugs in the Graft versus Host Disease (GVHD) Market 2019-2029
7.1 Temcell HS
7.1.1 Introduction
7.1.2 Safety & Efficacy
7.1.3 Advantages & Disadvantages
7.1.4 Total Temcell Sales, 2016-2027
7.2 Remicade
7.2.1 Introduction
7.2.2 Safety & Efficacy
7.2.3 Advantages & Disadvantages
7.2.4 Total Remicade Sales, 2016-2027
7.3 Lemtrada
7.3.1 Introduction
7.3.2 Safety & Efficacy
7.3.3 Advantages & Disadvantages
7.3.4 Total Lemtrada Sales, 2016-2027
7.4 Velcade
7.4.1 Introduction
7.4.2 Safety & Efficacy
7.4.3 Advantages & Disadvantages
7.4.4 Total Velcade Sales, 2016-2027
7.5 Gleevac
7.5.1 Introduction
7.5.2 Safety & Efficacy
7.5.3 Advantages & Disadvantages
7.5.4 Total Gleevac Sales, 2016-2027
7.6 Rapamune
7.6.1 Introduction
7.6.2 Safety & Efficacy
7.6.3 Advantages & Disadvantages
7.6.4 Total Rapamune Sales, 2016-2027
7.7 Enbrel
7.7.1 Introduction
7.7.2 Safety & Efficacy
7.7.3 Advantages & Disadvantages
7.7.4 Total Enbrel Sales, 2016-2027
7.8 Orencia
7.8.1 Introduction
7.8.2 Safety & Efficacy
7.8.3 Advantages & Disadvantages
7.8.4 Total Orencia Sales, 2016-2027
7.9 Nulojix
7.9.1 Introduction
7.9.2 Safety & Efficacy
7.9.3 Advantages & Disadvantages
7.9.4 Total Nulojix Sales, 2016-2027
7.10 Grafalon (ATG-Fresenius S)
7.10.1 Introduction
7.10.2 Safety & Efficacy
7.10.3 Advantages & Disadvantages
7.10.4 Total ATG-Fresenius Sales, 2016-2027
8 Emerging Therapies in the Graft versus Host Disease (GVHD) Market 2019-2029
8.1 Leukotac (inolimomab)
8.1.1 Introduction
8.1.2 Clinical Development
8.1.3 Total Leukotac Sales, 2016-2027
8.2 Begedina (begelomab)
8.2.1 Introduction
8.2.2 Clinical Development
8.2.3 Total Begelomab Sales, 2016-2027
8.3 Budesonide/Budenofalk (effeverscent)
8.3.1 Introduction
8.3.2 Clinical Development
8.3.3 Total Budesonide/Budenofalk Sales, 2016-2027
9 Global Graft versus Host Disease (GVHD) Market Drivers & Barriers
9.1 Market Drivers
9.1.1 Orphan Designation
9.1.2 Increased clinical & Pre-clinical studies with positive results
9.1.3 Increased Collaborations & Acquisitions
9.1.4 Competition among biotech and pharmaceutical giants
9.1.5 Wide range of targets
9.2 Market Barriers
9.2.1 Side-effects of approved drugs
9.2.2 Economic Burden
9.2.3 Challenges in Drug Development
9.2.4 Social Burden
10 SWOT Analysis
11 Conclusion
11.1 GVHD Market Forecast
11.2 GVHD Regional Market Forecast
11.3 GVHD Market Segments
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Tables
Table 1.1 Global GVHD Market: Revenue ($m), AGR (%), CAGR (%) by Region, 2016-2020
Table 2.1 Definition of Acute and Chronic GvHD
Table 2.2 Glucksberg Clinical Stage of Acute GvHD
Table 2.3 Glucksberg Grade of Acute GvHD
Table 2.4 Global Scoring of cGvHD
Table 3.1 Global GVHD Market: Revenue ($m) and Market Share (%) by Segment, 2016
Table 4.1 Key Events and their Market Impact (2013-2027)
Table 4.2 Global GVHD Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 4.3 Global GVHD by Treatment Type Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.1 Global GVHD Market Forecast 2016-2027 ($m), AGR %, CAGR %)
Table 6.1 Global GVHD Market: Revenue ($m) and Market Share (%) by Region, 2016
Table 6.2 United States GVHD Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.3 United States GVHD Market Forecast Segmented by Treatment Type Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.4 U.S. GVHD Market Forecast by Products: Revenue ($m), 2016-2027
Table 6.5 U.S. GVHD Patient Number Forecast, 2013-2026
Table 6.6 U.S. GVHD Patient Number Forecast, 2019-2029
Table 6.7 Japan GVHD Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.8 Japan GVHD Market Forecast Segmented by Treatment Type Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.9 Japan GVHD Market Forecast by Products: Revenue ($m), 2016-2027
Table 6.10 Japan GVHD Patient Number Forecast, 2013-2026
Table 6.11 Japan GVHD Patient Number Forecast, 2019-2029
Table 6.12 France GVHD Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.13 France GVHD Market Forecast Segmented by Treatment Type Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.14 France GVHD Market Forecast by Products: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.15 France GVHD Patient Number Forecast, 2013-2026
Table 6.16 France GVHD Patient Number Forecast, 2019-2029
Table 6.17 Germany GVHD Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.18 Germany GVHD Market Forecast Segmented by Treatment Type Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.19 Germany GVHD Market Forecast by Products: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.20 Germany GVHD Patient Number Forecast, 2013-2026
Table 6.21 Germany GVHD Patient Number Forecast, 2019-2029
Table 6.22 Italy GVHD Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.23 Italy GVHD Market Forecast Segmented by Treatment Type Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.24 Italy GVHD Market Forecast by Products: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.25 Italy GVHD Patient Number Forecast, 2013-2026
Table 6.26 Italy GVHD Patient Number Forecast, 2019-2029
Table 6.27 Spain GVHD Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.28 Spain GVHD Market Forecast Segmented by Treatment Type Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.29 Spain GVHD Market Forecast by Products: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.30 Spain GVHD Patient Number Forecast, 2013-2026
Table 6.31 Spain GVHD Patient Number Forecast, 2019-2029
Table 6.32 United Kingdom GVHD Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.33 United Kingdom GVHD Market Forecast Segmented by Treatment Type Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.34 United Kingdom GVHD Market Forecast by Products: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.35 United Kingdom GVHD Patient Number Forecast, 2013-2026
Table 6.36 United Kingdom GVHD Patient Number Forecast, 2019-2029
Table 7.1 Temcell Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.2 Remicade Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.3 Lemtrada Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.4 Velcade Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.5 Gleevac Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.6 Rapamune Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.7 Enbrel Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.8 Orencia Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.9 Nulojix Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.10 ATG-Fresenius Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027Table 8.1 Leukotac Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 8.2 Begelomab Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 8.3 Budesonide/Budenofalk Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027Table 11.1 Global Graft versus Host Disease (GVHD) Market: Revenue ($m), AGR (%), CAGR (%), 2016, 2022, 2027
Table 11.2 Global GVHD Market: Revenue ($m), AGR (%), CAGR (%) by Region, 2016, 2022, 2027
Table 11.3 Global Graft versus Host Disease (GVHD) Market: Revenue ($m), AGR (%), CAGR (%) by Segment, 2016, 2022, 2027
List of Figures
Figure 2.1 Initiation and Evolution of GvHD
Figure 3.1 Global GVHD Market: Revenue ($m) by Segment, 2016
Figure 3.2 Global GVHD: Market Share (%) by Segment, 2016
Figure 4.1 Global GVHD Market: Revenue ($bn) 2016-2027
Figure 4.2 Global GVHD Market Forecast Segmented by Treatment Type: 2016-2027 ($m)
Figure 5.1 Global GVHD Market by product 2016-2027 ($m)
Figure 5.2 Global GVHD Market by Product: Market Share (%), 2016
Figure 5.3 Global GVHD Market by Product: Market Share (%), 2022
Figure 5.4 Global GVHD Market by Product: Market Share (%), 2027
Figure 6.1 Global GVHD Market: Revenue ($m) by Region, 2016
Figure 6.2 Global GVHD: Market Share (%) by Region, 2016
Figure 6.3 United States GVHD market Forecast: 2016-2027 ($m, AGR %)
Figure 6.4 United States GVHD Market Forecast Segmented by Treatment Type: 2016-2027 ($m)
Figure 6.5 United States GVHD Market by Treatment Type: Market Share (%), 2016
Figure 6.6 United States GVHD Market by Treatment Type: Market Share (%), 2022
Figure 6.7 United States GVHD Market by Treatment Type: Market Share (%), 2027
Figure 6.8 U.S. GVHD Patient Number Forecast, 2013-2026
Figure 6.9 U.S. GVHD Patient Number Forecast, 2019-2029
Figure 6.10 Japan GVHD market Forecast:2016-2027 ($m, AGR %)
Figure 6.11 Japan GVHD Market Forecast Segmented by Treatment Type: 2016-2027 ($m)
Figure 6.12 Japan GVHD Market by Treatment Type: Market Share (%), 2016
Figure 6.13 Japan GVHD Market by Treatment Type: Market Share (%), 2022
Figure 6.14 Japan GVHD Market by Treatment Type: Market Share (%), 2027
Figure 6.15 Japan GVHD Patient Number Forecast, 2013-2026
Figure 6.16 Japan GVHD Patient Number Forecast, 2019-2029
Figure 6.17 France GVHD market Forecast: 2016-2027 ($m, AGR %)
Figure 6.18 France GVHD Market Forecast Segmented by Treatment Type: 2016-2027 ($m)
Figure 6.19 France GVHD Market by Treatment Type: Market Share (%), 2016
Figure 6.20 France GVHD Market by Treatment Type: Market Share (%), 2022
Figure 6.21 France GVHD Market by Treatment Type: Market Share (%), 2027
Figure 6.22 France GVHD Patient Number Forecast, 2013-2026
Figure 6.23 France GVHD Patient Number Forecast, 2019-2029
Figure 6.24 Germany GVHD market Forecast: 2016-2027 ($m, AGR %)
Figure 6.25 Germany GVHD Market Forecast Segmented by Treatment Type: 2016-2027 ($m)
Figure 6.26 Germany GVHD Market by Treatment Type: Market Share (%), 2016
Figure 6.27 Germany GVHD Market by Treatment Type: Market Share (%), 2022
Figure 6.28 Germany GVHD Market by Treatment Type: Market Share (%), 2027
Figure 6.29 Germany GVHD Patient Number Forecast, 2013-2026
Figure 6.30 Germany GVHD Patient Number Forecast, 2019-2029
Figure 6.31 Italy GVHD market Forecast: 2016-2027 ($m, AGR %)
Figure 6.32 Italy GVHD Market Forecast Segmented by Treatment Type: 2016-2027 ($m)
Figure 6.33 Italy GVHD Market by Treatment Type: Market Share (%), 2016
Figure 6.34 Italy GVHD Market by Treatment Type: Market Share (%), 2022
Figure 6.35 Italy GVHD Market by Treatment Type: Market Share (%), 2027
Figure 6.36 Italy GVHD Patient Number Forecast, 2013-2026
Figure 6.37 Italy GVHD Patient Number Forecast, 2019-2029
Figure 6.38 Spain GVHD market Forecast: 2016-2027 ($m, AGR %)
Figure 6.39 Spain GVHD Market Forecast Segmented by Treatment Type: 2016-2027 ($m)
Figure 6.40 Spain GVHD Market by Treatment Type: Market Share (%), 2016
Figure 6.41 Spain GVHD Market by Treatment Type: Market Share (%), 2022
Figure 6.42 Spain GVHD Market by Treatment Type: Market Share (%), 2027
Figure 6.43 Spain GVHD Patient Number Forecast, 2013-2026
Figure 6.44 Spain GVHD Patient Number Forecast, 2019-2029
Figure 6.45 United Kingdom GVHD market Forecast: 2016-2027 ($m, AGR %)
Figure 6.46 United Kingdom GVHD Market Forecast Segmented by Treatment Type: 2016-2027 ($m)
Figure 6.47 United Kingdom GVHD Market by Treatment Type: Market Share (%), 2016
Figure 6.48 United Kingdom GVHD Market by Treatment Type: Market Share (%), 2022
Figure 6.49 United Kingdom GVHD Market by Treatment Type: Market Share (%), 2027
Figure 6.50 United Kingdom GVHD Patient Number Forecast, 2013-2026
Figure 6.51 United Kingdom GVHD Patient Number Forecast, 2019-2029
Figure 7.1 Temcell: Sales ($m), 2016-2027
Figure 7.2 Remicade: Sales ($m), 2016-2027
Figure 7.3 Lemtrada: Sales ($m), 2016-2027
Figure 7.4 Velcade: Sales ($m), 2016-2027
Figure 7.5 Gleevac: Sales ($m), 2016-2027
Figure 7.6 Rapamune: Sales ($m), 2016-2027
Figure 7.7 Enbrel: Sales ($m), 2016-2027
Figure 7.8 Orencia: Sales ($m), 2016-2027
Figure 7.9 Nulojix: Sales ($m), 2016-2027
Figure 7.10 ATG-Fresenius: Sales ($m), 2016-2027
Figure 8.1 Leukotac: Sales ($m), 2016-2027
Figure 8.2 Begelomab: Sales ($m), 2016-2027
Figure 8.3 Budesonide/Budenofalk: Sales ($m), 2016-2027
Figure 11.1 Global Graft versus Host Disease (GVHD) Market: Revenue ($m), 2016, 2022, 2027
Figure 11.2 Global Graft versus Host Disease (GVHD) Market: Revenue ($m), by Region, 2016, 2022, 2027
Figure 11.3 Global Graft versus Host Disease (GVHD) Market: Revenue ($m) by Segment, 2016, 2022, 2027
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
